MAXHEALTH.BO
Max Healthcare Institute LimitedExplain this page
Arphra AIPlain-English read on Max Healthcare Institute Limited’s valuationRatios & metrics
Profitability, returns on capital, growth, and credit — all derived from the historical income statement, balance sheet, and cash flow rows in our data warehouse.
A snapshot of the latest fiscal year’s margins, returns on capital, balance-sheet strength and efficiency, computed from the income statement, balance sheet and cash-flow rows. Source income / balance / cash_flow.
Valuation multiples
| In USD | FY 2026 |
|---|---|
| Headline | |
| Market cap | $932.26B |
| Enterprise value | $960.38B |
| Multiples | |
| P / E | — |
| P / B | — |
| EV / EBITDA | — |
| EV / Sales | 11.47 |
| EV / FCF | 645.46 |
| Yields | |
| Earnings yield | +1.55% |
| Free cash flow yield | +0.16% |
| Dividend yield | — |
Profitability
| In USD | FY 2026 |
|---|---|
| Margins | |
| Gross margin | +78.62% |
| Operating margin | +21.45% |
| EBITDA margin | +28.15% |
| EBIT margin | +22.82% |
| Pre-tax margin | +20.01% |
| Net margin | +17.23% |
| Cost structure | |
| Cost of revenue / sales | +21.38% |
| R&D intensity | 0.00% |
| SG&A intensity | +21.42% |
| Effective tax rate | +13.92% |
Returns on capital
| In USD | FY 2026 |
|---|---|
| Returns | |
| Return on equity (ROE) | +13.42% |
| Return on assets (ROA) | +8.37% |
| Return on capital (ROC) | +12.63% |
| Return on invested capital (ROIC) | +10.14% |
| Asset turnover | +48.60% |
| DuPont · ROE decomposition | |
| Net margin | +17.23% |
| Asset turnover (× revenue / assets) | +48.60% |
| Equity multiplier (× assets / equity) | +160.34% |
Activity & efficiency
| In USD | FY 2026 |
|---|---|
| Turnover | |
| Asset turnover | 0.49 |
| Fixed-asset turnover | 1.11 |
| Inventory turnover | 15.66 |
| Receivables turnover | 8.63 |
| Payables turnover | 2.08 |
| Days outstanding | |
| Days sales outstanding (DSO) | 42.27 |
| Days inventory outstanding (DIO) | 23.30 |
| Days payables outstanding (DPO) | 175.17 |
| Cash conversion cycle | -109.59 |
Cash flow quality
| In USD | FY 2026 |
|---|---|
| Operating CF / Net income | 1.13 |
| FCF / Net income | 0.10 |
| FCF margin | +1.78% |
| OCF margin | +19.51% |
| CapEx / Revenue | +17.73% |
| CapEx / D&A | 3.32 |
| Stock-based comp / Revenue | +0.58% |
Per-share & shareholder yield
| In USD | FY 2026 |
|---|---|
| EPS · diluted | 14.75 |
| EPS · basic | 14.84 |
| Book value / share | 109.91 |
| Tangible BV / share | 48.47 |
| Sales / share | 85.64 |
| Operating CF / share | 16.70 |
| Free cash flow / share | 1.52 |
| Dividends / share | 1.49 |
| Payout ratio | +10.10% |
| Retention ratio | +89.90% |
Growth
| In USD | FY 2026 | CAGR |
|---|---|---|
| Top-line | ||
| Revenue · YoY | — | — |
| Gross profit · YoY | — | — |
| Profit | ||
| Operating income · YoY | — | — |
| EBITDA · YoY | — | — |
| Net income · YoY | — | — |
| Operating | ||
| EBIT · YoY | — | — |
| R&D · YoY | — | — |
| Per-share | ||
| EPS · diluted · YoY | — | — |
| EPS · basic · YoY | — | — |
Credit & leverage
| In USD | FY 2026 |
|---|---|
| Leverage | |
| Total debt | $34.78B |
| Net debt | $28.13B |
| Net debt / EBITDA | 1.19 |
| Debt / equity | 0.32 |
| Debt / assets | +20.19% |
| Equity / assets | +62.37% |
| Coverage | |
| EBITDA / interest expense | 10.03 |
| Operating income / interest | 7.64 |
| Interest expense | $2.35B |
| Liquidity | |
| Current ratio | 0.89 |
| Quick ratio | 0.80 |
| Cash ratio | 0.30 |
| Working capital | -$2.42B |
| Working capital / revenue | -2.89% |
Historical multiples · μ ± σ bands
3 fiscal-year-end observations from key_metrics. Mean is dashed; light-green band is ±1σ, light-red band ±2σ. The dot marks the most recent value; the cheap / fair / rich verdict uses z-score against the issuer's own history (yields inverted — a high yield is cheap).
Sourced from key_metrics + financial_ratios (loaded by load_fundamentals_extended.py).
| Metric | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| P / E | — | — | — |
| P / B | — | — | — |
| EV / EBITDA | — | — | — |
| EV / Sales | 11.47x | 15.40x | 14.74x |
| Earnings yield | 1.5% | 1.0% | 1.3% |
| FCF yield | 0.2% | 0.5% | 0.4% |
| Metric | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Gross margin | — | — | — |
| Operating margin | — | — | — |
| Net margin | — | — | — |
| ROE | 13.4% | 11.5% | 12.6% |
| ROA | 8.4% | 7.1% | 8.8% |
| ROIC | 9.9% | 16.3% | 15.9% |
| Metric | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Debt / equity | — | — | — |
| Net debt / EBITDA | 1.19 | 1.27 | 0.22 |
| Interest coverage | — | — | — |
| Current ratio | 0.89x | 0.88x | 1.37x |
| Quick ratio | — | — | — |
Methodology. ROE / ROA / ROC use period-end balance-sheet denominators (no average-of- period smoothing). ROIC = Operating Income × (1 − inferred effective tax rate) over invested capital, with the effective tax inferred from net-to-operating income when both are positive and a 25% default otherwise. Net debt / EBITDA, debt ratios, and interest-coverage ratios are calculated point-in-time at each fiscal year-end. TTM = trailing 4 quarters (income / cash flow summed, balance sheet = most-recent quarterly snapshot). Through-cycle CAGR in the Growth panel uses the geometric mean of first-to-last period growth across the window (positive values only).